Published in Antimicrob Agents Chemother on July 01, 1999
Correlation between the resistance genotype determined by multiplex PCR assays and the antibiotic susceptibility patterns of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (2000) 3.26
Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Antimicrob Agents Chemother (2001) 1.02
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol (2008) 0.94
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. Antimicrob Agents Chemother (2000) 0.93
Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother (2004) 0.85
Antimicrobial Resistance, Biofilm Formation and mecA Characterization of Methicillin-Susceptible S. aureus and Non-S. aureus of Beef Meat Origin in Egypt. Front Microbiol (2016) 0.76
Prevalence of the Antibiotic Resistance Genes in Coagulase-Positive-and Negative-Staphylococcus in Chicken Meat Retailed to Consumers. Front Microbiol (2016) 0.75
Staphylococcus saprophyticus Recovered from Humans, Food, and Recreational Waters in Rio de Janeiro, Brazil. Int J Microbiol (2017) 0.75
Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli. Antimicrob Agents Chemother (2004) 0.75
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J Bacteriol (1992) 3.95
Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis (1991) 3.12
Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob Agents Chemother (1991) 2.82
Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1991) 2.80
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis (1998) 2.67
Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother (1994) 2.11
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis (1998) 1.94
Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother (1998) 1.74
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
Clinical importance of identifying coagulase-negative staphylococci isolated from blood cultures: evaluation of MicroScan Rapid and Dried Overnight Gram-Positive panels versus a conventional reference method. J Clin Microbiol (1998) 1.68
The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother (1997) 1.65
Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis (1997) 1.63
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.61
The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers. Diagn Microbiol Infect Dis (1990) 1.37
Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother (1998) 1.36
Identification of DNA gyrase A mutations in ciprofloxacin-resistant isolates of Salmonella typhimurium from men and cattle in Germany. Microb Drug Resist (1995) 1.31
Staphylococcus hominis subsp. novobiosepticus subsp. nov., a novel trehalose- and N-acetyl-D-glucosamine-negative, novobiocin- and multiple-antibiotic-resistant subspecies isolated from human blood cultures. Int J Syst Bacteriol (1998) 1.31
Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother (1998) 1.31
Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (1996) 1.29
Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.17
Rapid identification by specific PCR of coagulase-negative staphylococcal species important in hospital infection. J Med Microbiol (1997) 1.15
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother (1998) 1.04
Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods. Diagn Microbiol Infect Dis (1994) 0.89
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1998) 0.88
Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob Agents Chemother (1998) 0.88
The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types. Clin Infect Dis (1998) 0.87
Susceptibility of Staphylococcus species and subspecies to fleroxacin. Antimicrob Agents Chemother (1991) 0.82
In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test. Diagn Microbiol Infect Dis (1999) 0.81
DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother (1996) 0.81
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Chemotherapy (1998) 0.79
Trends in antibiotic resistance of staphylococci over an eight-year period: differences in the emergence of resistance between coagulase positive and coagulase-negative staphylococci. Microb Drug Resist (1998) 0.79
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
Species identification of coagulase-negative staphylococci from urinary tract isolates. J Clin Microbiol (1978) 2.67
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol (1997) 1.82
Enterobacter cloacae: bacteremia, epidemiology, and antibiotic resistance. Rev Infect Dis (1982) 1.80
Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania. . Microb Drug Resist (2000) 1.57
Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance. J Infect Dis (1986) 1.55
Characteristics of Serratia marcescens containing a plasmid coding for gentamicin resistance in nosocomial infections. J Infect Dis (1981) 1.45
Evidence for a chromosomal site specifying amikacin resistance in multiresistant Serratia marcescens. Antimicrob Agents Chemother (1982) 1.44
Immunoblots, antimicrobial resistance, and bacteriophage typing of oxacillin-resistant Staphylococcus aureus. J Clin Microbiol (1988) 1.44
Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child (1985) 1.29
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother (1993) 1.26
Pseudobacteremia. Infect Control (1984) 1.25
Plasmids as epidemiologic markers in nosocomial gram-negative bacilli: experience at a university and review of the literature. Rev Infect Dis (1986) 1.23
In vivo sequence variation of the human immunodeficiency virus type 1 env gene: evidence for recombination among variants found in a single individual. AIDS Res Hum Retroviruses (1991) 1.22
Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis (1996) 1.21
Cefotaxime therapy. Evaluation of its effect on bacterial meningitis, CSF drug levels, and bactericidal activity. Arch Intern Med (1983) 1.15
Bactericidal action of modulated ultraviolet light on six groups of Salmonella. Infect Control Hosp Epidemiol (1991) 1.08
Dissemination of trimethoprim-resistant clones of Shigella sonnei in Bulgaria. J Infect Dis (1989) 1.06
Spinal syphilis: the problem of fluorescent treponemal antibody in the cerebrospinal fluid. South Med J (1977) 1.03
Activity of cephalosporins against methicillin-susceptible and methicillin-resistant, coagulase-negative staphylococci: minimal effect of beta-lactamase. Antimicrob Agents Chemother (1980) 0.99
Antibiotic cycling: is it ready for prime time? Infect Control Hosp Epidemiol (2000) 0.98
Relatedness of strains of methicillin-resistant coagulase-negative Staphylococcus colonizing hospital personnel and producing bacteremias in a neonatal intensive care unit. Pediatr Infect Dis J (1992) 0.97
Endemic Serratia marcescens infection in a neonatal intensive care nursery associated with gastrointestinal colonization. Pediatr Infect Dis (1985) 0.96
A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance. Res Microbiol (2001) 0.95
Nephelometric detection of soluble immune complexes: methodology and clinical applications. Int Arch Allergy Appl Immunol (1979) 0.95
Effect of peritoneal dialysis solution on the antimicrobial activity of cephalosporins. Nephron (1982) 0.94
Trimethoprim-sulfamethoxazole therapy of pulmonary melioidosis. Am Rev Respir Dis (1976) 0.94
Epidemic methicillin-gentamicin-resistant Staphylococcus aureus in a neonatal intensive care unit. Am J Dis Child (1989) 0.93
Aminoglycoside resistance in Pseudomonas aeruginosa isolated from cystic fibrosis patients. Am J Clin Pathol (1984) 0.92
Molecular epidemiology of sequential nursery epidemics caused by multiresistant Klebsiella pneumoniae. J Pediatr (1983) 0.91
Sequence analysis of dru regions from methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococcal isolates. Microb Drug Resist (2001) 0.90
Methicillin-resistant Staphylococcus aureus outbreak at a Veterans' Affairs Medical Center: importance of carriage of the organism by hospital personnel. Infect Control Hosp Epidemiol (1990) 0.89
Characteristics of gentamicin resistance in nosocomial infections. Am J Med Sci (1980) 0.88
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1998) 0.88
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens. AIDS Res Hum Retroviruses (2001) 0.87
Molecular epidemiology of trimethoprim-resistant Shigella boydii serotype 2 strains from Bulgaria. J Clin Microbiol (1992) 0.86
Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children. J Med Virol (1998) 0.86
In vivo R-plasmid transfer in a patient with a mixed infection of shigella dysentery. Epidemiol Infect (1994) 0.86
An outbreak of Pseudomonas cepacia bacteremia associated with a contaminated intra-aortic balloon pump. J Thorac Cardiovasc Surg (1988) 0.85
Smoking, the soldier, and the army. Mil Med (1977) 0.85
Increased frequency of large R-plasmids in Klebsiella pneumoniae colonizing patients with spinal cord injury. Diagn Microbiol Infect Dis (1993) 0.83
Tuberculous arachnoiditis. J Pediatr (1975) 0.82
Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria. Antimicrob Agents Chemother (1984) 0.81
Effect of inline filtration on postinfusion phlebitis. Clin Pharm (1983) 0.80
Use, misuse, and cost of parenteral cephalosporins at a county hospital. South Med J (1980) 0.79
Mycobacterium fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am J Med (1981) 0.79
Cost-effective antimicrobial therapy: an approach for physicians and community hospitals. J S C Med Assoc (1986) 0.78
Effect of formulary restriction of cefotaxime usage. Arch Intern Med (1985) 0.78
Endocarditis associated with disseminated group B streptococcal infection. Am J Med Sci (1978) 0.77
Case report 89. Skeletal Radiol (1979) 0.77
Cytomegalovirus pneumonia in sickle cell disease. Chest (1984) 0.77
Gonococcal endocarditis. Sex Transm Dis (1978) 0.77
Protected transbronchial needle aspiration and protected specimen brush in the diagnosis of pneumonia. Am Rev Respir Dis (1987) 0.76
Respiratory syncytial virus infection in a cardiac surgery intensive care unit. J Thorac Cardiovasc Surg (1994) 0.76
HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors. Antivir Ther (2001) 0.76
Gram stain. Ann Intern Med (1998) 0.75
Enterobacter plasmids: molecular epidemiology. Infect Control Hosp Epidemiol (1995) 0.75
Risk factors associated with the acquisition of amikacin-resistant gram-negative bacilli in central New Jersey hospitals. Infect Control Hosp Epidemiol (1998) 0.75
Cefotaxime therapy of serious bacterial infection in adults. Antimicrob Agents Chemother (1982) 0.75
Mass in tuberculous peritonitis. Ann Intern Med (1973) 0.75
Miss Elsie Beale--old and alone. Midwife Health Visit (1969) 0.75
Old problems with new names. JAMA (1982) 0.75
Trimethoprim-sulfamethoxzole: a rational antibiotic combination with many potential indications. J S C Med Assoc (1976) 0.75
Gangrene of the tongue. Arch Intern Med (1994) 0.75
A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro. Antiviral Res (1999) 0.75
Nerve conduction studies in natural rubella. Ann Neurol (1977) 0.75
Isomeric DNA ladder formation of a plasmid encoding tobramycin resistance from Escherichia coli. J Antimicrob Chemother (1991) 0.75
MRSA colonization. Infect Control (1987) 0.75
Polyarteritis overlap syndrome with extensive bowel infarction. Am J Gastroenterol (1980) 0.75
Nosocomial infection rates at a General Army Hospital. Am J Surg (1977) 0.75